online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 9 of 10
Up
ECPB 2020, 90(2): 64–67
https://doi.org/10.25040/ecpb2020.02.064
Reviews

Polymorphisms of paraoxonase genes – the common background of gallbladder and heart diseases

L. M. STRILCHUK
Abstract

Paraoxonases are produced by liver. These enzymes hydrolize and detoxify oxidized low density lipoproteins and homocysteine and have an important value in atherosclerosis development. With the aim of estimation the modern points of view onto the role of paraoxonase genes mutations in te development of cardiovascular and hepatobiliary disorders we made a literature search. It was revealed that paraoxonases are produced by liver and are associated with high density lipoproteins, hydrolize and detoxify oxidized low density lipoproteins and homocysteine. That’s why their decrease leads to the high risk of development of atherosclerosis, diabetes mellitus, cholelithiasis, age-related diseases, and metabolic syndrome. Polymorphisms of genes of paraoxonase 1 (PON1-Q192R; -gln191 to arg; PON1-L55M (LL, MM, LM); G-907C, A-162G and C-108T), paraoxonase 2 (Ala/Gly in 148 position and Ser/Cys in 311 position) and paraoxonase 3 (c.449G >A, SNPs A10340C, A2115T and introne variant of PON3 INS2+3651(A>G)(rs10487132)) are associated with cardiovascular and biliary diseases independently of lipid profile and smoking status due to activation of the oxidative stress and inflammation. Polymorphisms of paraoxonase genes are the common genetic background of heart and gallbladder disorders.

Added: 20.05.2020

Keywords: paraoxonases, genetic polymorphism, cardiovascular diseases, cholelithiasis, biliary diseases

Full text: PDF (Ukr) 285K

References
  1. 1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-9. 2003;107:2775-9. doi.org/10.1016/S0140-6736(06)69044-2
  2. 2. Ata N, Kucukazman M, Yavuz B, Bulus H, Dal K, Ertugrul DT et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011;25:274-6. doi.org/10.1155/2011/356761
  3. 3. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M et al. Paraoxo- nase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 2001;276:44444-9. doi.org/10.1074/jbc.M105660200
  4. 4. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484-90. doi.org/10.1161/01.CIR.0000023623.87083.4F
  5. 5. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation.
  6. 6. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 2003;34:774-84. doi.org/10.1016/S0891-5849(02)01429-6
  7. 7. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-76. doi.org/10.1001/jama.299.11.1265
  8. 8. Levy D, Reichert CO, Bydlowski SP. Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview. Antioxidants (Basel). 2019;8(5):pii:E118. doi.org/10.3390/antiox8050118
  9. 9. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 2000;20:2441-7. doi.org/10.1161/01.ATV.20.11.2441
  10. 10. Shi J, Zhang S, Tang M, Liu X, Li T, Han H et al. Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer's disease in Chinese. Brain Res. Mol. Brain Res. 2004;120:201-4. doi.org/10.1016/j.molbrainres.2003.10.018
  11. 11. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 2001;21:542-547. doi.org/10.1161/01.ATV.21.4.542
  12. 12. Shih DM, Yu JM, Vergnes L, Dali-Youcef N, Champion MD, Devarajan A et al. PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis. FASEB J. 2015;29(4):1185-97. doi.org/10.1096/fj.14-260570
  13. 13. Atamer A, Atamer Y, Can AS. Response to: Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis. Saudi J Gastroenterol. 2016;22(1):84-5. doi.org/10.4103/1319-3767.173769
  14. 14. Agilli M, Aydin FN, Aydin I. Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis. Saudi J Gastroenterol. 2014;20(3):203-4. doi.org/10.4103/1319-3767.133039
  15. 15. Koksal H, Kurban S. Total oxidant status, total antioxidant status, and paraoxonase and arylesterase activities during laparoscopic cholecystectomy. Clinics (Sao Paulo). 2010;65(3):285- 90. doi.org/10.1590/S1807-59322010000300008


Програмування - Roman.im